Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Respiratory Syncytial Virus Infections 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Suspensions × Clear all
NCT06597916 2024-11-27

RSV Vaccination in Immunocompromised Patients.

Medical University of Vienna

Phase 2 Recruiting
200 enrolled

Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡